Proceedings of the 18th Collegium Internationale Neuro-Psychopharmacologicum Congress, Part 1 |
Contents
18th Collegium Internationale | 2 |
SYMPOSIA | 9 |
New Developments | 17 |
Copyright | |
74 other sections not shown
Common terms and phrases
abnormalities activity affinity agonists alcohol alprazolam antagonists antipsychotic anxiety disorders associated behavioral benzodiazepines binding biochemical Biol brain brofaromine buspirone calcium cells cerebral cholinergic chronic circadian Clin clinical clozapine cognitive compared concentrations controls correlated cortex cortical cortisol D2 receptors decreased dementia depressed patients desipramine diagnostic disease dopamine dose drugs efficacy endogenous episodes ethanol factors fluoxetine frontal function gene genetic glutamate haloperidol hippocampus hormone imipramine impairment increased induced inhibition inhibitors interaction latency lithium major depression mechanisms Medical metabolism migraine mRNA neuroleptics neurons Neurosci neurotransmitter NMDA normal observed opioid panic disorder peptides pharmacokinetic Pharmacol pharmacological placebo plasma levels potential protein Psychiatry Psychopharmacology rates rats rCBF regions release remoxipride response reuptake rhythm risperidone schizophrenia schizophrenic patients selective serotonergic serotonin side effects significant significantly sleep specific stimulation stress striatum studies subjects subunits suggest suicide symptoms syndrome therapeutic treatment triazolam tricyclic antidepressants uptake